# EDGAR Filing Document

**Accession Number:** 0000883241
**File Stem:** 0001193125-26-241911
**Filing Date:** 2026-5
**Character Count:** 57695
**Document Hash:** 60cbd5a8bfae8cf2239c8ae34f46750b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-241911.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001193125-26-241911

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260527

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SYNOPSYS INC
- **CENTRAL INDEX KEY:** 0000883241
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 561546236
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19807
- **FILM NUMBER:** 261026304

**BUSINESS ADDRESS:**
- **STREET 1:** 675 ALMANOR AVE
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085
- **BUSINESS PHONE:** 6505845000

**MAIL ADDRESS:**
- **STREET 1:** 675 ALMANOR AVE
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (date of earliest event reported): May 27, 2026

## SYNOPSYS, INC.

#### (Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-19807** | **56-1546236** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### 675 Almanor Ave

#### Sunnyvale, California 94085

#### (Address of principal executive offices) (Zip code)

#### Registrant's telephone number, including area code: (650) 584-5000

#### N/A

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock (par value of $0.01 per share) | SNPS | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On May 27, 2026, Synopsys, Inc. ("**Synopsys**", "**we**", "**our**", or "**us**") issued a press release announcing the financial results of its second fiscal quarter ended April 30, 2026. A copy of the press release is furnished and attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto and incorporated by reference herein, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission by Synopsys whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) <u>Exhibits</u>

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Title** |
| 99.1 | [Press release dated May 27, 2026 containing Synopsys, Inc.'s results of operations for its second fiscal quarter ended April 30, 2026.](d126227dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** |
| Dated: May 27, 2026 | By: | /S/ JANET LEE |
|  |  | **Janet Lee** |
|  |  | **General Counsel and Corporate Secretary** |

---

## Exhibit 99.1

**Exhibit 99.1** 

**PRESS RELEASE** 

**INVESTOR CONTACT**:

Tushar Jain

Synopsys, Inc.

650-584-4289

<u>Synopsys-ir@synopsys.com</u>

**EDITORIAL CONTACT**:

Cara Walker

Synopsys, Inc.

650-584-5000

<u>corp-pr@synopsys.com</u>

**Synopsys Posts Financial Results for Second Quarter Fiscal Year 2026** 

***Announces Plan for September 2026 Investor Day***

<u>Results Summary</u> 

• Quarterly revenue of $2.276 billion, above prior guidance; quarterly GAAP earnings per diluted share (EPS)
of $0.09, and non-GAAP EPS of $3.35

• Raising expectations for full-year total revenue to $9.665 billion at the midpoint, driven by strong
performance across the business and an EPS-neutral Ansys channel-related accounting impact, partly offset by the impending close of the Processor IP Solutions business

• Raising full-year non-GAAP EPS guidance to $14.76 at the midpoint on
expanded operating margin driven by strong cost discipline and accelerating synergies

**SUNNYVALE, Calif.** – **May 27, 2026** – <u>Synopsys, Inc.</u> (Nasdaq: <u>SNPS</u>) today reported results for its second quarter of fiscal year 2026. Revenue for the second quarter of fiscal year 2026 was $2.276 billion, compared to $1.604 billion for the second quarter of fiscal year 2025.

"Synopsys delivered a strong second quarter with solid execution and strength across the business," said Sassine Ghazi, Synopsys president and CEO. "AI is scaling semiconductor demand, architectural diversity and complexity of chips and the systems they power—driving demand across our portfolio. Our momentum, leadership roadmap, and deep customer engagements are a strong foundation for sustained growth and margin expansion as we solve our customers' toughest engineering challenges."

------

"Second quarter revenue and non-GAAP EPS exceeded guidance. Our continued focus on execution and financial discipline sets us up for a strong second half," said Shelagh Glaser, CFO of Synopsys. "We are raising our targets for revenue, operating margin, EPS, and free cash flow for the year, as we drive greater efficiency across the business."

The company plans to host an Investor Day on Sept. 30, during which management will provide additional detail regarding the company's long-term financial targets and strategy to capitalize on its sizable opportunity as the leader in engineering solutions from silicon to systems.

*GAAP Results* 

On a U.S. generally accepted accounting principles (GAAP) basis, net income for the second quarter of fiscal year 2026 was $17.1 million, or $0.09 per diluted share, compared to $349.2 million, or $2.24 per diluted share, for the second quarter of fiscal year 2025.

*Non-GAAP Results* 

On a non-GAAP basis, net income for the second quarter of fiscal year 2026 was $643.7 million, or $3.35 per diluted share, compared to non-GAAP net income of $572.7 million, or $3.67 per diluted share, for the second quarter of fiscal year 2025.

For a reconciliation of net income, earnings per diluted share and other measures on a GAAP and non-GAAP basis, see "GAAP to Non-GAAP Reconciliation" in the accompanying tables below.

*Business Segments* 

Synopsys reports revenue and operating income in two segments: (1) Design Automation, which includes our advanced silicon design, verification products and services, Ansys products, system integration products and services, digital, custom and field programmable gate array IC design software, verification software and hardware products, manufacturing software products and other; and (2) Design IP, which includes our logic libraries, embedded memories, wired interface IP, memory interface IP, security IP, and embedded processors.

**Financial Targets** 

Synopsys also provided its consolidated financial targets for the third quarter and full fiscal year 2026. These targets assume no further changes to export control restrictions or the current U.S. government "Entity List" restrictions. These targets constitute forward-looking statements and are based on current expectations. For a discussion of factors that could cause actual results to differ materially from these targets, see "Forward-Looking Statements" below.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Third Quarter and Full Fiscal Year 2026 Financial Targets** | **Third Quarter and Full Fiscal Year 2026 Financial Targets** | **Third Quarter and Full Fiscal Year 2026 Financial Targets** | **Third Quarter and Full Fiscal Year 2026 Financial Targets** | **Third Quarter and Full Fiscal Year 2026 Financial Targets** |
| *(in millions, except per share amounts)* | *(in millions, except per share amounts)* | *(in millions, except per share amounts)* | *(in millions, except per share amounts)* | *(in millions, except per share amounts)* |
|  | **Range for Three Months<br>Ending**<br>**July 31, 2026** | **Range for Three Months<br>Ending**<br>**July 31, 2026** | **Range for Fiscal Year<br>Ending**<br>**October 31, 2026** | **Range for Fiscal Year<br>Ending**<br>**October 31, 2026** |
|  | **Low** | **High** | **Low** | **High** |
|  Revenue <sup>(1)</sup> | $2410 | $2460 | $9625 | $9705 |
|  GAAP Expenses | $2075 | $2125 | $8469 | $8599 |
|  Non-GAAP Expenses | $1440 | $1470 | $5675 | $5725 |
|  Non-GAAP Interest and Other Income (Expense), net | $(121) | $(117) | $(495) | $(485) |
|  Non-GAAP Tax Rate | 18% | 18% | 18% | 18% |
|  Outstanding Shares (fully diluted) | 192 | 194 | 192 | 194 |
|  GAAP EPS | $0.84 | $0.98 | $2.49 | $2.91 |
|  Non-GAAP EPS | $3.63 | $3.69 | $14.72 | $14.80 |
|  Operating Cash Flow |  |  | ~$2,300 | ~$2,300 |
|  Free Cash Flow <sup>(2)</sup> |  |  | ~$2,000 | ~$2,000 |
|  Capital Expenditures |  |  | ~$300 | ~$300 |

---

(1) Fiscal year 2026 revenue includes $2.96 billion of expected Ansys revenue (including $60 million
related to an accounting impact for Ansys channel partners), and reflects the impact of approximately $110 million of the divested Optical Solutions Group and PowerArtist RTL businesses, and $40 million related to the expected divestiture
of the Processor IP Solutions business.

(2) Free cash flow is calculated as cash provided from operating activities less capital expenditures.

---

| |
|:---|
| **Fiscal Year 2026 Revenue Target Raise Breakdown** |
| *(in millions)* |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | For Fiscal Year Ending | For Fiscal Year Ending | For Fiscal Year Ending | For Fiscal Year Ending | For Fiscal Year Ending | For Fiscal Year Ending | For Fiscal Year Ending | For Fiscal Year Ending |
|  | October 31, 2026 | October 31, 2026 | October 31, 2026 | October 31, 2026 | October 31, 2026 | October 31, 2026 | October 31, 2026 | October 31, 2026 |
|  | Prior Guidance<br>Mid-Point | Business<br>Performance | Business<br>Performance | Ansys Channel<br>Accounting<br>Impact | Ansys Channel<br>Accounting<br>Impact | Processor IP<br>Solutions<br>Divestiture | Processor IP<br>Solutions<br>Divestiture | New Guidance<br>Mid-Point |
|  Revenue | $9610 | + $| 35 | + $| 60 | ($| 40) | $9665 |

---

For a reconciliation of Synopsys' third quarter and fiscal year 2026 targets, including expenses, earnings per diluted share and other measures on a GAAP and non-GAAP basis, a discussion of the financial targets that we are not able to reconcile without unreasonable efforts and a discussion of why management believes such measurements provide useful information to investors, see "GAAP to Non-GAAP Reconciliation" in the accompanying tables below.

------

**Earnings Call Open to Investors** 

Synopsys will hold a conference call for financial analysts and investors today at 2:00 p.m. Pacific Time. A live webcast of the call will be available in the investor relations portion of Synopsys' corporate website at <u>www.synopsys.com</u>. Synopsys uses its website as a tool to disclose important information about Synopsys and comply with its disclosure obligations under Regulation Fair Disclosure. A webcast replay will also be available on the corporate website from approximately 5:30 p.m. Pacific Time today through the time Synopsys announces its results for the third quarter of fiscal year 2026.

**Availability of Final Financial Statements** 

Synopsys will include final financial statements for the second quarter of fiscal year 2026 in its quarterly report on Form 10-Q to be filed with the Securities and Exchange Commission (SEC) and available at www.sec.gov on or before June 9, 2026.

*Continuing Operations* 

On Sept. 30, 2024, Synopsys completed the sale of its Software Integrity business. Unless otherwise noted, Synopsys' Software Integrity business has been presented as a discontinued operation in the Synopsys' consolidated financial statements for all periods presented herein and all financial results and targets are presented herein on a continuing operations basis.

<u>Reconciliation of Second Quarter Fiscal Year 2026 Results</u> 

The following tables reconcile the specific items excluded from GAAP in the calculation of non-GAAP net income, earnings per diluted share, and tax rate for the periods indicated below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **GAAP to Non-GAAP Reconciliation of Second Quarter Fiscal Year 2026 Results** | **GAAP to Non-GAAP Reconciliation of Second Quarter Fiscal Year 2026 Results** | **GAAP to Non-GAAP Reconciliation of Second Quarter Fiscal Year 2026 Results** | **GAAP to Non-GAAP Reconciliation of Second Quarter Fiscal Year 2026 Results** | **GAAP to Non-GAAP Reconciliation of Second Quarter Fiscal Year 2026 Results** |
| *(unaudited and in thousands, except per share amounts)* | *(unaudited and in thousands, except per share amounts)* | *(unaudited and in thousands, except per share amounts)* | *(unaudited and in thousands, except per share amounts)* | *(unaudited and in thousands, except per share amounts)* |
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **April 30,** | **April 30,** | **April 30,** | **April 30,** |
|  | **2026** | **2025** | **2026** | **2025** |
|  GAAP net income from continuing operations attributed to Synopsys | $17105 | $349232 | $82063 | $644915 |
|  Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | 403631 | 11656 | 807866 | 24252 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | 222303 | 201723 | 481027 | 388002 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | 115894 |  | 234176 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition/divestiture related items | 23649 | 69514 | 39241 | 144343 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on sale of strategic investments |  | 2435 |  | 2435 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tax adjustments | (138848) | (61862) | (282170) | (158076) |
|  Non-GAAP net income from continuing operations attributed to Synopsys | $643734 | $572698 | $1362203 | $1045871 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **April 30,** | **April 30,** | **April 30,** | **April 30,** |
|  | **2026** | **2025** | **2026** | **2025** |
|  GAAP net income from continuing operations per diluted share attributed to Synopsys | $0.09 | $2.24 | $0.43 | $4.13 |
|  Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | 2.10 | 0.07 | 4.22 | 0.16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | 1.16 | 1.29 | 2.51 | 2.48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | 0.60 |  | 1.22 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition/divestiture related items | 0.12 | 0.45 | 0.20 | 0.92 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on sale of strategic investments |  | 0.02 |  | 0.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tax adjustments | (0.72) | (0.40) | (1.47) | (1.02) |
|  Non-GAAP net income from continuing operations per diluted share attributed to Synopsys | $3.35 | $3.67 | $7.11 | $6.69 |
|  Shares used in computing net income per diluted share amounts: | 192144 | 156088 | 191580 | 156218 |

---

**GAAP to Non-GAAP Tax Rate Reconciliation** 

*(unaudited)* 

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br>**April 30, 2026** | **Six Months Ended**<br>**April 30, 2026** |
|  GAAP effective tax rate | 12.5% | 17.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | 9.7% | 4.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | (2.1)% | (2.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income tax adjustments <sup>(1)</sup> | (2.1)% | (1.6)% |
|  Non-GAAP effective tax rate | 18.0% | 18.0% |

---

(1) The tax adjustments are primarily due to differences in the tax rate effect of certain deductions, such as the
deduction for foreign-derived intangible income and credits.

------

<u>Reconciliation of 2026 Targets</u>

The following tables reconcile the specific items excluded from GAAP in the calculation of non-GAAP targets for the periods indicated below.

---

| | | |
|:---|:---|:---|
| **GAAP to Non-GAAP Reconciliation of Third Quarter Fiscal Year 2026 Targets** | **GAAP to Non-GAAP Reconciliation of Third Quarter Fiscal Year 2026 Targets** | **GAAP to Non-GAAP Reconciliation of Third Quarter Fiscal Year 2026 Targets** |
| *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* |
|  | **Range for Three Months Ending** | **Range for Three Months Ending** |
|  | **July 31, 2026** | **July 31, 2026** |
|  | **Low** | **High** |
|  Target GAAP expenses | $2075000 | $2125000 |
|  Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | (400000) | (405000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | (230000) | (240000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | (5000) | (10000) |
|  Target non-GAAP expenses | $1440000 | $1470000 |
|  | **Range for Three Months Ending** | **Range for Three Months Ending** |
|  | **July 31, 2026** | **July 31, 2026** |
|  | **Low** | **High** |
|  Target GAAP earnings per diluted share attributed to Synopsys | $0.84 | $0.98 |
|  Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | 2.10 | 2.07 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | 1.24 | 1.19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | 0.05 | 0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tax adjustments | (0.60) | (0.58) |
|  Target non-GAAP earnings per diluted share attributed to Synopsys | $3.63 | $3.69 |
|  Shares used in non-GAAP calculation (midpoint of target range) | 193000 | 193000 |

---

---

| | | |
|:---|:---|:---|
| **GAAP to Non-GAAP Reconciliation of Full Fiscal Year 2026 Targets** | **GAAP to Non-GAAP Reconciliation of Full Fiscal Year 2026 Targets** | **GAAP to Non-GAAP Reconciliation of Full Fiscal Year 2026 Targets** |
| *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* |
|  | **Range for Fiscal Year Ending** | **Range for Fiscal Year Ending** |
|  | **October 31, 2026** | **October 31, 2026** |
|  | **Low** | **High** |
|  Target GAAP expenses | $8469241 | $8599241 |
|  Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | (1610000) | (1620000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | (945000) | (965000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | (200000) | (250000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition/divestiture related items <sup>(1)</sup> | (39241) | (39241) |
|  Target non-GAAP expenses | $5675000 | $5725000 |

---

------

---

| | | |
|:---|:---|:---|
|  | **Range for Fiscal Year Ending** | **Range for Fiscal Year Ending** |
|  | **October 31, 2026** | **October 31, 2026** |
|  | **Low** | **High** |
|  Target GAAP earnings per diluted share attributed to Synopsys | $2.49 | $2.91 |
|  Adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | 8.39 | 8.34 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | 5.00 | 4.90 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | 1.30 | 1.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition/divestiture related items <sup>(1)</sup>  | 0.20 | 0.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tax adjustments | (2.66) | (2.59) |
|  Target non-GAAP earnings per diluted share attributed to Synopsys | $14.72 | $14.80 |
|  Shares used in non-GAAP calculation (midpoint of target range) | 193000 | 193000 |

---

(1) Adjustments reflect actual expenses incurred by Synopsys as of April 30, 2026, and do not fully reflect
all potential adjustments for future periods for the reasons set forth in "GAAP to Non-GAAP Reconciliation" below.

**Forward-Looking Statements** 

This press release and the investor conference call contain forward-looking statements, including, but not limited to, statements concerning our short-term and long-term financial targets, expectations and objectives; our businesses, business segments, strategies, partnerships, initiatives and opportunities, including, among other things, the reallocation of resources in our Design IP segment to higher growth opportunities and planned restructuring activities; industry growth and technological trends, such as artificial intelligence, including our development and planned commercialization thereof; business and market outlook; the potential impact of the uncertain macroeconomic environment and global economic conditions on our financial results; the impact of current and future U.S. and foreign trade regulations, government actions and regulatory changes, such as export control restrictions and tariffs; the ANSYS, Inc. (Ansys) integration and its expected impact, including expected synergies and the timing thereof, our ability to create joint solutions as a combined company, and related accounting changes; planned acquisitions or divestitures, including the expected completion of the sale of the Processor IP Solutions business, and their anticipated timing and impact; our key customers, customer concentration, customer engagement, customer demand and market expansion; results and

------

strategies related to our products, technology and services, including product development and our planned product releases and capabilities; the expected realization of our contracted but unsatisfied or partially unsatisfied performance obligations (backlog); planned stock repurchases; our expected tax rate; and the status, expected outcome or expected impact of litigation and/or regulatory investigations. These statements involve risks, uncertainties and other factors that could cause our actual results, time frames or achievements to differ materially from those expressed or implied in such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: macroeconomic conditions and geopolitical uncertainty in the global economy; uncertainty in the growth of the semiconductor and electronics industries; the highly competitive industry we operate in; actions by the U.S. or foreign governments, such as the imposition of additional export restrictions or tariffs; consolidation among our customers and our dependence on a relatively small number of large customers; risks and compliance obligations relating to the global nature of our operations; failure to realize the benefits expected from the transactions we complete, including the acquisition of Ansys (the Ansys Merger) or unexpected difficulties or expenditures arising therefrom; risks related to inaccuracies in, or failures to achieve, our operational and business metrics or forecasts of growth; and more. Additional information on potential risks, uncertainties and other factors that could affect Synopsys' results is included in filings we make with the SEC from time to time, including in the sections entitled "Risk Factors" in our latest Annual Report on Form 10-K and in our latest Quarterly Report on Form 10-Q. The financial information contained in this press release should be read in conjunction with the consolidated financial statements and notes thereto included in Synopsys' most recent reports on Forms 10-K and 10-Q, each as may be amended from time to time. Synopsys' financial results for its second quarter of fiscal year 2026 are not necessarily indicative of Synopsys' operating results for any future periods.

**Effectiveness of Information** 

The targets included in this press release, the statements made during the earnings conference call, the information contained in the financial supplement and the corporate overview presentation, each of which are available in the investor relations portion of Synopsys' corporate website at <u>www.synopsys.com</u> (collectively, the Earnings Materials), represent Synopsys' expectations and beliefs as of May 27, 2026. Although these Earnings Materials are expected to remain available on Synopsys' website through the time Synopsys announces its results for the third quarter of fiscal year 2026, their continued availability through such time does not mean that Synopsys is reaffirming or confirming their continued validity. Synopsys undertakes no duty, and does not intend, to update any forward-looking statement, including any targets, provided in the Earnings Materials, whether as a result of new information, future events or otherwise, unless required by law.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** |
| **Unaudited Condensed Consolidated Statements of Income** | **Unaudited Condensed Consolidated Statements of Income** | **Unaudited Condensed Consolidated Statements of Income** | **Unaudited Condensed Consolidated Statements of Income** | **Unaudited Condensed Consolidated Statements of Income** |
| *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* |
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **April 30,** | **April 30,** | **April 30,** | **April 30,** |
|  | **2026** | **2025** | **2026** | **2025** |
|  Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Time-based products | $945624 | $828326 | $1897165 | $1656564 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upfront products | 546252 | 510676 | 1287782 | 878800 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total products revenue | 1491876 | 1339002 | 3184947 | 2535364 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maintenance and service | 784109 | 265264 | 1499836 | 524217 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total revenue | 2275985 | 1604266 | 4684783 | 3059581 |
|  Cost of revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Products | 232897 | 216216 | 475299 | 385058 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maintenance and service | 148597 | 94471 | 295335 | 187008 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | 248356 | 7660 | 496598 | 16256 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total cost of revenue | 629850 | 318347 | 1267232 | 588322 |
|  Gross margin | 1646135 | 1285919 | 3417551 | 2471259 |
|  Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development | 700124 | 553979 | 1415112 | 1107195 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sales and marketing | 381998 | 215021 | 778373 | 424220 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General and administrative | 172418 | 136497 | 355150 | 303583 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | 155275 | 3996 | 311268 | 7996 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | 115894 |  | 234176 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating expenses | 1525709 | 909493 | 3094079 | 1842994 |
|  Operating income | 120426 | 376426 | 323472 | 628265 |
|  Interest expense | (133364) | (94336) | (296079) | (105475) |
|  Other income (expense), net | 32214 | 114101 | 70936 | 164518 |
|  Income before income taxes | 19276 | 396191 | 98329 | 687308 |
|  Provision for income taxes | 2408 | 47181 | 16745 | 40887 |
|  Net income from continuing operations | 16868 | 349010 | 81584 | 646421 |
|  Loss from discontinued operations, net of income taxes |  | (3900) |  | (3900) |
|  Net income | 16868 | 345110 | 81584 | 642521 |
|  Less: Net income (loss) attributed to non-controlling interest and redeemable non-controlling interest | (237) | (222) | (479) | 1506 |
|  Net income attributed to Synopsys | $17105 | $345332 | $82063 | $641015 |
|  Net income (loss) attributed to Synopsys  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuing operations | $17105 | $349232 | $82063 | $644915 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discontinued operations |  | (3900) |  | (3900) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net income | $17105 | $345332 | $82063 | $641015 |
|  Net income (loss) per share attributed to Synopsys - basic: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuing operations | $0.09 | $2.25 | $0.43 | $4.17 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discontinued operations |  | (0.02) |  | (0.03) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basic net income per share | $0.09 | $2.23 | $0.43 | $4.14 |
|  Net income (loss) per share attributed to Synopsys - diluted: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continuing operations | $0.09 | $2.24 | $0.43 | $4.13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discontinued operations |  | (0.03) |  | (0.03) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted net income per share | $0.09 | $2.21 | $0.43 | $4.10 |
|  Shares used in computing per share amounts: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Basic | 191464 | 154927 | 190513 | 154666 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted | 192144 | 156088 | 191580 | 156218 |

---

------

---

| | | |
|:---|:---|:---|
| **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** |
| **Unaudited Condensed Consolidated Balance Sheets** | **Unaudited Condensed Consolidated Balance Sheets** | **Unaudited Condensed Consolidated Balance Sheets** |
| *(in thousands, except par value amounts)* | *(in thousands, except par value amounts)* | *(in thousands, except par value amounts)* |
|  | **April 30, 2026** | **October 31, 2025** |
|  **ASSETS:** |  |  |
|  Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $2412472 | $2888030 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-term investments | 71966 | 72929 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total cash, cash equivalents and short-term investments | 2484438 | 2960959 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable, net | 1267305 | 1505427 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | 441836 | 365190 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid and other current assets | 1195391 | 1180526 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Current assets held for sale | 48248 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 5437218 | 6012102 |
|  Property and equipment, net | 714744 | 696693 |
|  Operating lease right-of-use assets, net | 697112 | 702008 |
|  Goodwill | 26853807 | 26899215 |
|  Intangible assets, net | 11875418 | 12679591 |
|  Deferred income taxes | 113642 | 112159 |
|  Other long-term assets | 1197086 | 1122693 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $&nbsp;&nbsp;&nbsp;&nbsp;46889027 | $48224461 |
|  **LIABILITIES AND STOCKHOLDERS' EQUITY:** |  |  |
|  Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable and accrued liabilities | $1185204 | $1326211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease liabilities | 135523 | 128205 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue | 2419876 | 2245961 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-term debt | 22117 | 22117 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Current liabilities held for sale | 27912 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 3790632 | 3722494 |
|  Long-term operating lease liabilities | 670475 | 680698 |
|  Long-term deferred revenue | 389419 | 382557 |
|  Long-term debt | 10013845 | 13462398 |
|  Other long-term liabilities | 1547591 | 1649299 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 16411962 | 19897446 |
|  Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred stock, $0.01 par value: 2,000 shares authorized; none outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common stock, $0.01 par value: 400,000 shares authorized; 191,444 and 185,994 shares outstanding, respectively | 1928 | 1860 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capital in excess of par value | 20565562 | 18640947 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retained earnings | 10397550 | 10315487 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treasury stock, at cost: 593 and 1,222 shares, respectively | (242827) | (398278) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accumulated other comprehensive loss | (244082) | (232414) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Synopsys stockholders' equity | 30478131 | 28327602 |
|  Non-controlling interest | (1066) | (587) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity | 30477065 | 28327015 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $46889027 | $48224461 |

---

------

---

| | | |
|:---|:---|:---|
| **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** |
| **Unaudited Condensed Consolidated Statements of Cash Flows** | **Unaudited Condensed Consolidated Statements of Cash Flows** | **Unaudited Condensed Consolidated Statements of Cash Flows** |
| *(in thousands)* | *(in thousands)* | *(in thousands)* |
|  | **Six Months Ended April 30,** | **Six Months Ended April 30,** |
|  | **2026** | **2025** |
|  CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
|  Net income | $81584 | $642521 |
|  Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization and depreciation | 907177 | 96838 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction of operating lease right-of-use assets | 72852 | 51728 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of capitalized costs to obtain revenue contracts | 41158 | 25405 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | 481027 | 388186 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allowance for credit losses | 14842 | 15940 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on sale of strategic investments |  | 2435 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gain on sale of building |  | (51385) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on divestitures, net of transaction costs |  | 8299 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of bridge financing costs |  | 40411 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of debt issuance costs | 16903 | 2348 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred income taxes | (121045) | (237170) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other | (153) | (181) |
|  Net changes in operating assets and liabilities, net of effects from acquisitions and dispositions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable | 234512 | (74098) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | (85832) | (39766) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid and other current assets | 44649 | (140472) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other long-term assets | (87060) | (36058) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable and accrued liabilities | (114629) | (242529) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease liabilities | (74166) | (48617) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income taxes | (122420) | (36870) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue | 196367 | (37412) |
|  Unrealized loss on settlement of interest rate treasury lock |  | (121643) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by operating activities | 1485766 | 207910 |
|  CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceeds from maturities of short-term investments | 11180 | 35461 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceeds from sales of short-term investments | 3656 | 22015 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchases of short-term investments | (13903) | (47558) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchases of strategic investments | (781) | (3368) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchases of property and equipment, net | (89518) | (96303) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceeds from sale of building |  | 74279 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceeds from business divestiture, net of cash divested |  | 70082 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other |  | (611) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) investing activities | (89366) | 53997 |
|  CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceeds from debt, net of issuance costs |  | 10034464 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repayment of debt | (3462369) | (1289) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Issuances of common stock | 116136 | 118308 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Payments for taxes related to net share settlement of equity awards | (217884) | (166872) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common stock issuance for private placement | 2000000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchase of equity forward contract | (37500) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchases of treasury stock | (262500) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redemption of redeemable non-controlling interest |  | (30000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) financing activities | (1864117) | 9954611 |
|  Effect of exchange rate changes on cash, cash equivalents and restricted cash | (9247) | 8186 |
|  Net change in cash, cash equivalents and restricted cash | (476964) | 10224704 |
|  Cash, cash equivalents and restricted cash, beginning of year | 2893721 | 3898729 |
|  Cash, cash equivalents and restricted cash, end of period | $2416757 | $14123433 |

---

------

Synopsys provides segment information, namely revenue, adjusted segment operating income and adjusted segment operating margin, in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 280, Segment Reporting. Synopsys' chief operating decision maker (CODM) is our Chief Executive Officer. In evaluating our business segments, the CODM considers the income and expenses that the CODM believes are directly related to those segments. The CODM does not allocate certain operating expenses managed at a consolidated level to our business segments and, as a result, the reported operating income and operating margin do not include these unallocated expenses as shown in the table below. These unallocated expenses are presented in the table below to provide a reconciliation of the total adjusted operating income from segments to our consolidated operating income:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** | **SYNOPSYS, INC.** |
| **Business Segment Reporting <sup>(1)</sup>** | **Business Segment Reporting <sup>(1)</sup>** | **Business Segment Reporting <sup>(1)</sup>** | **Business Segment Reporting <sup>(1)</sup>** | **Business Segment Reporting <sup>(1)</sup>** |
| *(in millions)* | *(in millions)* | *(in millions)* | *(in millions)* | *(in millions)* |
|  | **Three Months Ended<br>April 30, 2026** | **Three Months Ended<br>April 30, 2025** | **Six Months Ended<br>April 30, 2026** | **Six Months Ended<br>April 30, 2025** |
|  Revenue by segment |  |  |  |  |
|  - Design Automation | $1821.8 | $1122.3 | $3823.6 | $2142.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *% of Total* | 80.0% | 70.0% | 81.6% | 70.0% |
|  - Design IP | $454.2 | $482.0 | $861.2 | $917.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *% of Total* | 20.0% | 30.0% | 18.4% | 30.0% |
|  Adjusted operating income by segment |  |  |  |  |
|  - Design Automation | $789.1 | $458.8 | $1736.6 | $863.4 |
|  - Design IP | $110.6 | $150.5 | $176.8 | $277.1 |
|  Adjusted operating margin by segment |  |  |  |  |
|  - Design Automation | 43.3% | 40.9% | 45.4% | 40.3% |
|  - Design IP | 24.4% | 31.2% | 20.5% | 30.2% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Total Adjusted Segment Operating Income Reconciliation <sup>(1)</sup>** | **Total Adjusted Segment Operating Income Reconciliation <sup>(1)</sup>** | **Total Adjusted Segment Operating Income Reconciliation <sup>(1)</sup>** | **Total Adjusted Segment Operating Income Reconciliation <sup>(1)</sup>** | **Total Adjusted Segment Operating Income Reconciliation <sup>(1)</sup>** |
| *(in millions)* | *(in millions)* | *(in millions)* | *(in millions)* | *(in millions)* |
|  | **Three Months Ended<br>April 30, 2026** | **Three Months Ended<br>April 30, 2025** | **Six Months Ended<br>April 30, 2026** | **Six Months Ended<br>April 30, 2025** |
|  GAAP total operating income – as reported | $120.4 | $376.4 | $323.5 | $628.3 |
|  Other expenses managed at consolidated level |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of acquired intangible assets | 403.6 | 11.7 | 807.9 | 24.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation <sup>(2)</sup> | 222.3 | 201.7 | 481.0 | 388.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restructuring charges | 115.9 |  | 234.2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition/divestiture related items <sup>(3)</sup> | 23.6 | 39.6 | 39.2 | 100.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-qualified deferred compensation plan | 13.8 | (20.1) | 27.6 | (0.5) |
|  Total adjusted segment operating income | $899.7 | $609.3 | $1913.4 | $1140.5 |

---

---

| |
|:---|
| (1) Synopsys manages the business on a long-term, annual basis, and considers quarterly fluctuations of revenue and profitability as normal elements of our business. Amounts may not foot due to rounding. |
| (2) The adjustment includes non-GAAP expenses attributable to non-controlling interest and redeemable non-controlling interest. |
| (3) The adjustment excludes the amortization of bridge financing costs entered into in connection with the Ansys Merger that was recorded in interest expense, and certain divestiture related items that were recorded in other income (expense), net in our unaudited condensed consolidated statements of income. |

---

------

**GAAP to Non-GAAP Reconciliation** 

Synopsys continues to provide all information required in accordance with GAAP but acknowledges evaluating its ongoing operating results may not be as useful if an investor is limited to reviewing only GAAP financial measures. Accordingly, Synopsys presents non-GAAP financial measures in reporting its financial results to provide investors with an additional tool to evaluate Synopsys' operating results in a manner that focuses on what Synopsys believes to be its core business operations and what Synopsys uses to evaluate its business operations and for internal budgeting and resource allocation purposes. This press release includes non-GAAP earnings per diluted share, non-GAAP net income and non-GAAP tax rate for the periods presented. It also includes future estimates for non-GAAP expenses, non-GAAP interest and other income (expense), net, non-GAAP tax rate, non-GAAP earnings per diluted share and free cash flow. These non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

When possible, Synopsys provides a reconciliation of non-GAAP financial measures to their most closely applicable GAAP financial measures. Synopsys is unable to provide a full reconciliation of certain third quarter and full fiscal year 2026 non-GAAP financial targets to the corresponding GAAP financial measures on a forward-looking basis because Synopsys believes that it would not be possible for it to have the required information necessary to quantitatively reconcile such measures with sufficient precision without unreasonable efforts due to, among other things, the potential variability and limited predictability of the excluded adjustment items necessary for a full reconciliation such as certain acquisition/divestiture related items, tax deduction variability, changes in the fair value of non-qualified deferred compensation plan, and gains (losses) on the sale of strategic investments. For the same reasons, Synopsys is unable to address the probable significance of the unavailable information.

Synopsys' management does not itself, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, as superior to, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are meant to supplement, and be viewed in conjunction with, the corresponding GAAP financial measures. Synopsys' management believes the presentation of non-GAAP financial measures, when shown

------

in conjunction with the corresponding GAAP financial measures, provides useful information to investors allowing them to view financial and business trends relating to our financial condition and results of operations through the eyes of management. Synopsys' management evaluates and makes decisions about our business operations using both GAAP financial measures and non-GAAP financial measures to help facilitate internal comparisons to Synopsys' historical operating results and forecasted targets, planning and forecasting in subsequent periods and comparisons to competitors' operating results.

The following are descriptions of the adjustments made to reconcile non-GAAP financial measures (other than free cash flow, which is defined in the footnote to the *Financial Targets* table above) to the most directly comparable GAAP financial measures:

(i) *Amortization of acquired intangible assets.* We incur expenses from the amortization of acquired intangible assets, which may include impairment charges from write-downs of acquired intangible assets. Acquired intangible assets include, among other things, core/developed technology, customer relationships, contract rights, trademarks and trade names, and other intangibles related to acquisitions. We amortize the intangible assets over their estimated useful lives. We do not enter into acquisitions on a predictable cycle. The amount of an acquisition's purchase price allocated to intangible assets and their estimated useful lives can vary significantly and are unique to each acquisition. From time to time, we incur impairment charges due to write-downs of acquired intangible assets. We believe that the presentation of non-GAAP financial measures that adjust for the amortization of intangible assets, including impairment charges, provides investors and others with a consistent basis for comparison across accounting periods. We also exclude this item because such expenses are non-cash in nature and we believe the non-GAAP financial measures excluding this item provide meaningful supplemental information regarding our core operational performance and liquidity, and ability to invest in research and development and fund future acquisitions and capital expenditures.

(ii) *Stock-based compensation*. Stock-based compensation expenses consist primarily of expenses related to restricted stock units, stock options, employee stock purchase rights and other stock awards, including such expenses associated with acquisitions. We exclude stock-based compensation expense from our non-GAAP financial measures primarily because it is not an expense that typically requires or will require cash settlement by us. Further, the expense for the fair value of the stock-based instruments we utilize may bear little resemblance to the actual value realized upon the vesting or future exercise of the related stock-based awards and, therefore, is not used by management to assess the core profitability of our business operations.

------

(iii) *Acquisition/divestiture related items.* In connection with certain of our business combinations and/or divestitures, we incur significant expenses that we would not have otherwise incurred as part of our business operations. These expenses include, among other things, compensation expenses, professional fees and other direct expenses, concurrent restructuring activities and divestiture activities, including employee severance and other exit costs, bridge financing costs, costs related to integration activities, debt forgiveness, changes to the fair value of contingent consideration related to the acquired company, and amortization of the fair value difference of below-market value assets arising from arrangements entered into or acquired in conjunction with an acquisition. We also recognize the gains and losses from the mark-up of equity or cost method investments to fair value upon obtaining control through acquisition. We exclude these items because they are related to acquisitions and divestitures and have no direct correlation to the core operation of our business. Further, because we do not acquire or divest businesses on a predictable cycle and the terms of each transaction can vary significantly and are unique to each transaction, we believe it is useful to exclude such expenses when looking for a consistent basis for comparison across accounting periods.

(iv) *Restructuring charges.* We initiate restructuring activities to align our costs to our operating plans and business strategies based on then-current economic conditions, and such activities have a specific and defined term. Restructuring costs generally include severance and other termination benefits related to voluntary retirement programs, involuntary headcount reductions and facilities closures. Such restructuring costs include elimination of operational redundancy, permanent reductions in workforce and facilities closures and, therefore, are not considered by us to be a part of the core operation of our business and are not used by management when assessing the core profitability and performance of our business operations.

(v) *Gains (losses) on the sale of strategic investments.* We exclude gains and losses on the sale of equity investments in privately held companies because we do not believe they are reflective of our core business and operating results.

(vi) *Deferred compensation*. We exclude changes in the fair value of our non-qualified deferred compensation plan because we do not use these to assess the core profitability of our business operations.

------

(vii) *Income tax effect of non-GAAP pre-tax adjustments*. Excluding the income tax effect of non-GAAP pre-tax adjustments from the provision for income taxes assists investors in understanding the tax provision associated with those adjustments and the effect on net income. Beginning in fiscal year 2026, we transitioned from an annual non-GAAP tax rate to a three-year normalized non-GAAP tax rate of 18.0%. We believe this will provide better consistency across reporting periods by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency and do not necessarily reflect our normal operations. This rate is based on our projected annual rate through fiscal year 2028, primarily due to the completion of the acquisition of Ansys in the third quarter of fiscal year 2025 and the enactment of the One Big Beautiful Bill Act (the OBBB), which affects taxable income starting in fiscal year 2026 over the next several years. In projecting this rate, we evaluated our historical and projected mix of U.S. and international profit before tax, excluding the impact of stock-based compensation, the amortization of purchased intangibles and other GAAP only adjustments described above. We also considered other factors, including our current tax structure, U.S. tax law changes, such as the OBBB which impacts Synopsys' expensing of U.S. research expenditures commencing in fiscal year 2026, and changes to foreign derived intangible income commencing in fiscal year 2027.

**About Synopsys** 

Synopsys, Inc. (Nasdaq: SNPS) is the leader in engineering solutions from silicon to systems, enabling customers to rapidly innovate AI-powered products. We deliver industry-leading silicon design, IP, simulation and analysis solutions, and design services. We partner closely with our customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow. Learn more at <u>www.synopsys.com</u>.

*<sup>©</sup> 2026 Synopsys, Inc. All rights reserved. Synopsys, Ansys, the Synopsys and Ansys logos, and other Synopsys trademarks are available at <u>https://www.synopsys.com/company/legal/trademarks-brands.html</u>. Other company or product names may be trademarks of their respective owners.*